Previous 10 | Next 10 |
2023-11-02 18:08:12 ET Definitive Healthcare ( DH ) +17% . Castle Biosciences ( CSTL ) +14% . Funko ( FNKO ) +14% . Trupanion ( TRUP ) +14% . Innovative International Acquisition ( IOAC ) +12% . Fortinet ( FTNT ) -19%...
2023-11-02 16:17:33 ET Castle Biosciences press release ( NASDAQ: CSTL ): Q3 GAAP EPS of -$0.26 beats by $0.50 . Revenue of $61.5M (+66.2% Y/Y) beats by $12.94M . Raising full year 2023 revenue guidance to at least $200 million from at least $180 million. ...
Castle’s innovative pipeline initiative to develop a genomic test aimed at guiding systemic therapy selection for patients with moderate-to-severe atopic dermatitis, psoriasis and related conditions is targeted to launch by the end of 2025 Castle Biosciences, Inc. (Nasdaq: CSTL),...
Q3 2023 revenue increased 66% over Q3 2022 to $61 million Q3 2023 total test reports increased 52% over Q3 2022 Raising full year 2023 revenue guidance to at least $200 million from at least $180 million Conference call and webcast today at 4:30 p.m. ET Castle Bi...
Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...
Castle Biosciences Inc. (CSTL) is expected to report $-0.92 for Q3 2023
Two posters highlight ability of the TissueCypher test to identify higher- and lower-risk subsets of patients with Barrett’s esophagus than indicated by their clinicopathologic factors to guide risk-aligned patient care Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the third quarter and nine months ended Sept. 30, 2023, after the close of market on Thursday, Nov. 2, 2023. Com...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will share new data across its dermatologic portfolio of gene expression profile (GEP) tests at the 2023 Fall Clinical Dermatology Conference® (FC23),...
2023-10-15 08:05:05 ET Summary Castle Biosciences, Inc. has seen a significant decline in its stock value since early 2021, despite impressive revenue growth and a solid balance sheet. The company offers diagnostic and prognostic testing services for dermatological cancers, and an...
News, Short Squeeze, Breakout and More Instantly...
Castle Biosciences Inc. Company Name:
CSTL Stock Symbol:
NYSE Market:
Castle Biosciences Inc. Website:
Campaign will focus on empowering patients impacted by melanoma Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, has joined forces with television personality, wellness coach and founder of ALL IN by Teddi, host of the...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter and six months ended June 30, 2024, after the close of market on Monday, Aug. 5, 2024. Compan...
Castle earns recognition as an Arizona Top Workplace, a national Healthcare Industry Top Workplace and receives five Top Workplaces Culture Excellence Awards Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today annou...